Randomized Phase II Trial of Re-Irradiation and Concurrent Bevacizumab versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma (NRG Oncology/RTOG 1205): Initial Outcomes and RT Plan Quality…

@przybyszmd @SBRT_CR @JHuangRadonc @lauren_henke @PercyLeeMD @fabiomoraesmd @DrewMoghanaki @_ShankarSiva @fifimcdrmh @finn_corinne Here we’d likely consider max safe Re-resxn then re-RT a la RTOG 1205, maybe slightly slower schedule depending on location …

Randomized Phase II Trial of Re-Irradiation and Concurrent Bevacizumab versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma (NRG Oncology/RTOG 1205): Initial Outcomes and RT Plan Quality Report https://t.co/inqVj7RxKK